PURPOSE: The purpose of this study was to evaluate the effect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted. METHODS: This was an open-labeled, fixed-sequence study of bevacizumab with FOLFIRI (irinotecan, leucovorin, and infusional 5-fluorouracil). Pharmacokinetic assessments were conducted in cycles 1 and 3. RESULTS: Forty-five subjects were enrolled. No difference in dose-normalized AUC(0-last) for irinotecan and SN-38 between irinotecan administered alone or in combination with bevacizumab was identified. Leukopenia was associated with higher exposure to both irinotecan and SN-38. UGT1A1 polymorphisms were associated with variability in irinotecan PK. Gastrointestinal toxicity was associated with UGT1A6 genotype. No other associations between UGT1A genotypes and toxicity were detected. CONCLUSION: Bevacizumab does not affect irinotecan PK when administered concurrently. A variety of pharmacogenetic relationships may influence the pharmacokinetics of irinotecan and its toxicity.
PURPOSE: The purpose of this study was to evaluate the effect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted. METHODS: This was an open-labeled, fixed-sequence study of bevacizumab with FOLFIRI (irinotecan, leucovorin, and infusional 5-fluorouracil). Pharmacokinetic assessments were conducted in cycles 1 and 3. RESULTS: Forty-five subjects were enrolled. No difference in dose-normalized AUC(0-last) for irinotecan and SN-38 between irinotecan administered alone or in combination with bevacizumab was identified. Leukopenia was associated with higher exposure to both irinotecan and SN-38. UGT1A1 polymorphisms were associated with variability in irinotecan PK. Gastrointestinal toxicity was associated with UGT1A6 genotype. No other associations between UGT1A genotypes and toxicity were detected. CONCLUSION:Bevacizumab does not affect irinotecan PK when administered concurrently. A variety of pharmacogenetic relationships may influence the pharmacokinetics of irinotecan and its toxicity.
Authors: Leslie E Carlini; Neal J Meropol; John Bever; Michael L Andria; Todd Hill; Philip Gold; Andre Rogatko; Hao Wang; Rebecca L Blanchard Journal: Clin Cancer Res Date: 2005-02-01 Impact factor: 12.531
Authors: Clinton F Stewart; John C Panetta; Melinda A O'Shaughnessy; Stacy L Throm; Charles H Fraga; Thandranese Owens; Tiebin Liu; Catherine Billups; Carlos Rodriguez-Galindo; Amar Gajjar; Wayne L Furman; Lisa M McGregor Journal: J Clin Oncol Date: 2007-06-20 Impact factor: 44.544
Authors: Jessica M van der Bol; Ron H J Mathijssen; Walter J Loos; Lena E Friberg; Ron H N van Schaik; Maja J A de Jonge; André S Th Planting; Jaap Verweij; Alex Sparreboom; Floris A de Jong Journal: J Clin Oncol Date: 2007-06-11 Impact factor: 44.544
Authors: G G Chabot; D Abigerges; G Catimel; S Culine; M de Forni; J M Extra; M Mahjoubi; P Hérait; J P Armand; R Bugat Journal: Ann Oncol Date: 1995-02 Impact factor: 32.976
Authors: Aung Naing; Razelle Kurzrock; Angelika Burger; Sachin Gupta; Xiudong Lei; Naifa Busaidy; David Hong; Helen X Chen; Lawrence A Doyle; Lance K Heilbrun; Eric Rohren; Chaan Ng; Chandtip Chandhasin; Patricia LoRusso Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Michael Michael; Winston Liauw; Sue-Anne McLachlan; Emma Link; Annetta Matera; Michael Thompson; Michael Jefford; Rod J Hicks; Carleen Cullinane; Athena Hatzimihalis; Ian G Campbell; Simone Rowley; Phillip J Beale; Christos S Karapetis; Timothy Price; Mathew E Burge Journal: Cancer Chemother Pharmacol Date: 2021-03-23 Impact factor: 3.333
Authors: A Abajo; J Rodriguez; N Bitarte; R Zarate; V Boni; M Ponz; A Chopitea; E Bandres; J Garcia-Foncillas Journal: Br J Cancer Date: 2010-10-12 Impact factor: 7.640
Authors: Giuseppe Toffoli; Manish R Sharma; Elena Marangon; Bianca Posocco; Elizabeth Gray; Quan Mai; Angela Buonadonna; Blase N Polite; Gianmaria Miolo; Gianna Tabaro; Federico Innocenti Journal: Clin Cancer Res Date: 2016-08-09 Impact factor: 12.531
Authors: Sandhya Girish; Steven W Martin; Mark C Peterson; Lei K Zhang; Hong Zhao; Joseph Balthasar; Raymond Evers; Honghui Zhou; Min Zhu; Lewis Klunk; Chao Han; Eva Gil Berglund; Shiew-Mei Huang; Amita Joshi Journal: AAPS J Date: 2011-06-01 Impact factor: 4.009